Key result
Compound heterozygous variants in the MDN1 gene were significantly more frequent in patients with epilepsy compared to asymptomatic controls (OR 3.75), suggesting MDN1 is a susceptibility gene for epilepsy.
Why the study?
MDN1 plays a role in ribosome maturation and is expressed in the human brain, but MDN1 variants had not previously been reported in patients with epilepsy.
Do MDN1 variants increase susceptibility to epilepsy in patients with febrile seizures or secondary epilepsy?
Case-Control (n=2,233)
Yes
Do MDN1 variants increase susceptibility to epilepsy in patients with febrile seizures or secondary epilepsy?
Odds Ratio: 3.75 (95% CI 1.25–11.28)
Absolute Event Rate: 1.72% vs 0.46%
p-value: p=0.027
Compound heterozygous variants in the MDN1 gene are significantly associated with an increased susceptibility to epilepsy, particularly febrile seizures and secondary epilepsy.
This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: The Midasin AAA (ATPase associated with various activities) ATPase 1 (MDN1) gene, a member of the AAA protein family, plays a crucial role in ribosome maturation. MDN1 is expressed in the human brain throughout life, especially during early development and adulthood. However, MDN1 variants have not been previously reported in patients with epilepsy. This study aims to explore the association between MDN1 variants and epilepsy. METHODS: Trios-based whole-exome sequencing was performed in a cohort of patients with epilepsy susceptibility from the China Epilepsy Gene 1.0 Project. The excess, damaging effects, and molecular subregional implications of variants, as well as the spatio-temporal expression of MDN1, were analyzed to validate the gene-disease association. RESULTS: Compound heterozygous variants in MDN1 were identified in five unrelated patients with febrile seizures or secondary epilepsy. Three patients presented with febrile seizures/epilepsy with febrile seizures plus, while two patients developed epilepsy secondary to brain damage (five or seven years after). These variants were either absent or present at low frequencies in the control group, and exhibited statistically significant higher frequencies in the case group compared to controls. All the missense variants were predicted to be damaging by at least one in silico tool. In each pair of compound heterozygous variants, one allele was located in the AAA2-AAA3 domains, while the other allele was located in the linker domain or its vicinity. In contrast, most of the variants from the asymptomatic control group were located outside the AAA domains, suggesting a molecular subregional implication of the MDN1 variants. CONCLUSIONS: MDN1 is potentially a susceptibility gene for epilepsy.
MDN1 variants may increase epilepsy susceptibility; leaves open a genetic marker role pending replication.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) conducted a case-control in Epilepsy (n=2,233). MDN1 compound heterozygous variants vs. Asymptomatic controls was evaluated on Frequency of compound heterozygous MDN1 variants (OR 3.75, 95% CI 1.25-11.28, p=0.027). Compound heterozygous variants in the MDN1 gene were significantly more frequent in patients with epilepsy compared to asymptomatic controls (OR 3.75), suggesting MDN1 is a susceptibility gene for epilepsy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: